Introduction
Genetic abnormalities in head and neck squamous cell cancer have been studied extensively, and frequent changes have been found. A key motivation for investigating head and neck cancer genetics is to find prognostic indicators of patient survival or markers to select the type of treatment. Further understanding of head and neck cancer genetics may also permit the development of new cancer therapies. This article discusses information on changes in tumor suppressor genes and oncogenes, presents the current state of the art of molecular detection of head and neck cancer, and reviews the status and promise of gene therapy. Tumor Suppressor Genes Tumor suppressor genes have been intensely investigated in head and neck cancer. These genes act to limit growth of tumors by slowing or halting cell cycle progression, and mutations in tumor suppressor genes are commonly seen in head and neck cancer. Aberrations in specific tumor suppressor genes may be predictive of patient outcome.
p53
Dysfunction in the p53 tumor suppressor gene (located at 17p13) is implicated in many cancers, including head and neck cancer, and has received the most attention. The production of p53 is increased in response to cellular insults or DNA damage, and p53 then induces cell cycle arrest at the G 1 /S junction. If the damage is irreparable, p53 can initiate cell death by apoptosis. 1 The steady-state concentration of p53 in normal cells is low, and the half-life of normal (wild type) p53 is short. In contrast, if the p53 gene is mutated, the genetic product is often present in high concentrations. 2 Therefore, immunohistochemical (IHC) methods can be used to detect abnormal p53, although the exact protein that is stained is of questionable significance. Polymerase chain reaction (PCR)-based methods, such as direct sequencing of the p53 gene or loss of heterozygosity (LOH) analysis, also allow detection of mutant p53. LOH analysis detects the loss of a genome-specific allele and thus can detect changes that may not be apparent with IHC analysis.
In head and neck cancer, p53 mutations are present in 33% to 59% of tumors using PCR, LOH occurs in 38% of tumors, and abnormal IHC staining is seen in 37% to 76% of tumors (Table 1) . Unfortunately, the tumors that have mutations do not always have abnor- Given the large number of studies without a clear correlation between p53 status and survival, it is evident that mutation of p53 is not a powerful predictive marker. In general, the studies that did show a relationship between p53 and outcome found, as expected, that overexpression of p53 as detected by IHC or the presence of LOH or mutations are associated with recurrence or death. However, an analysis of the Veterans Affairs Laryngeal Cancer Study, in which patients were randomized to induction chemotherapy followed by radiation therapy vs surgery and postoperative radiation, found unexpectedly that p53 overexpression as detected by IHC was associated with an increased rate of organ preservation. 4 A further analysis of these same patients by direct sequencing for mutations reported worse survival with p53 mutations present. 18 The clinical utility of p53 mutations as a predictor of survival or as an aid in selecting the method of therapy is therefore unclear.
Retinoblastoma
Retinoblastoma (Rb, located at 13q14) is a key tumor suppressor gene involved in controlling the cell cycle. 27 Hypophosphorylated Rb binds and inactivates a transcription factor responsible for cell cycle progression (EF1). Mutation of Rb or loss of Rb activity can therefore cause unchecked cell growth.
IHC studies demonstrate Rb abnormalities (diminished expression) in 6% to 74% of head and neck cancers (Table 2) . LOH analysis demonstrates loss of an Rb allele in 14% to 59% of tumors. As with p53, there is no clear correlation between Rb mutation and poor outcome; however, two studies suggested that underexpression correlates with poor survival. 28, 34 One study found that LOH at p53 and Rb occurring simultaneously is associated with poorer survival. 17 
p16/p21/p27
The p16, p21, and p27 tumor suppressor genes act to modulate cell proliferation. The p16 gene (located at 9p21) produces p16 protein, which in turn inhibits phosphorylation of Rb, thus inhibiting the Rb-induced release of transcription factor EF1 and cell cycle progression. 40 The p21 and p27 genes (located at 6p21 and 14q32, respectively) produce proteins that are activated by p53 and induce cell cycle arrest. 41, 42 Abnormalities can be found using PCR, LOH analysis, or Western blotting, which can evaluate protein expression.
Abnormalities in p16 are common in head and neck cancers. PCR methods have shown mutations in 19% to 58% of tumors, while LOH analysis revealed allelic losses in 57% (Table 3) . IHC methods have shown low p16 expression in 55% to 89% of tumors. Low expression of p16 therefore occurs in the vast majority of head and neck cancers. A study examining p16 using PCR and Western blotting for the same set of tumors found mutated p16 in only 19% of tumors; however, decreased p16 expression was found in 69% of tumors. 39 Thus, aberrations in the regulation of p16 protein production are common in head and neck cancer. Transcriptional inactivation by hypermethylation of the p16 gene promoter may contribute to this downregulation. 48, 49 Abnormal p16 is associated with worse survival, increased recurrences, tumor progression, and nodal metastasis in many of the studies assessing patient outcome.
Expression of p21 was shown in 29% to 92% of head and neck tumors using IHC methods (Table 4) . There is no clear relationship between p21 staining and clinical parameters. Expression of p27 was demonstrated in 18% to 62% of tumors by IHC. The presence of p27 has been correlated with improved survival (Table 5) .
Oncogenes
Oncogenes produce proteins that promote cell and tumor growth. The cellular changes necessary for malignant transformation involve the activation of many oncogenes.
Cyclin D1
The cyclins are proteins that are involved in cell cycle regulation. The cyclin D1 gene product (CCND1, located at 11q13) phosphorylates Rb, leading to cell cycle progression. The activity of cyclin D1 may be inhibited by many tumor suppressor genes including p16, p21, and p27. 65 In assessing cyclin D1, multiple techniques have been used including IHC, fluorescence in situ hybridization (FISH) allowing detection of gene copy number, and Southern blotting techniques allowing quantification of gene copy number.
In head and neck cancers, cyclin D1 has been shown to be amplified in 36% of tumors using FISH and in 18% to 58% of tumors using Southern blotting, and it is overexpressed in 12% to 68% using IHC ( Table 6 ). Studies that showed a relationship between cyclin D1 and outcome found, as expected, that amplification or overexpression was associated with recurrence, nodal metastasis, or death. 
EGF/EGFR
Human epidermal growth factor receptor (EGFR, located at 7p12) is a transmembrane protein with intrinsic tyrosine kinase activity expressed primarily on cells of epithelial origin. EGFR regulates cell growth in response to activation by EGF and transforming growth factor-α (TGF-α) binding. 78 EGFR is overexpressed in head and neck tumors, leading to increased tyrosine kinase activity and cell proliferation. 79 In addition, tumors can overexpress EGF, causing autocrine stimulation of the EGFR.
EGFR expression is found in a high percentage of head and neck cancers (43% to 62%). 80, 81 EGFR expression has been correlated with worse survival; however, the studies are few, and there are negative studies. Blockage of EGFR receptors in cell lines inhibits tumor growth and has led to active clinical trials. 82 
STAT3
The STAT tyrosine kinase system has recently been the subject of much investigation. Activated EGFR activates STAT proteins through a complex mechanism. The activated STAT then induces cell proliferation.
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STAT3 expression and DNA binding are significantly increased in the mucosa of patients with head and neck cancer. 84 In addition, blocking EGFR expression leads to a decrease in STAT3 activation. 85 No studies have been performed to demonstrate an association between STAT activity and head and neck cancer survival, but this kinase appears to be involved in tumor progression.
Multiple Molecular Aberrations in Head and Neck Cancers
Multiple genetic abnormalities are present in head and neck cancers. The exact number and type of abnormality differs from tumor to tumor, resulting in different phenotypes. Evaluating the genotype of head and neck tumors at multiple loci may provide more prognostic information.
The multiple genetic abnormalities present in head and neck cancer cells can be evaluated at the chromosomal level using spectral karyotyping (SKY) and comparative genomic hybridization (CGH). The SKY technique involves labeling each chromosome with a unique colored marker. Rearrangements can be identified when a combination of colors is seen on a single derived chromosome. Using this technique, frequent breakpoints were found in multiple chromosomes of head and neck cancer cells. 86 Identification of rearrangement sites allows for investigation of candidate oncogenes and tumor suppressor genes at these locations. Similar information can be obtained using CGH, in which tumor DNA is labeled with a specific colored marker and hybridized with DNA isolated from normal cells and stained with a different marker. Differences in gene copy number can be determined by the relative amount of staining. CGH has revealed frequent losses and gains on multiple chromosomes. 87 LOH analysis provides a rapid method of screening for multiple genetic abnormalities. In a study of 68 head and neck cancers, significant LOH was seen at chromosome bands 3p21, 3p25-26, 8pter-21.1, 13q14, and 17p12. LOH at more than two loci was correlated with a poor prognosis. 88 A study of 43 head and neck tumors also revealed that tumors with abnormalities in more than one gene (p53, Rb, q16, cyclin D1, p16, p21, and p27 were tested) had a poorer prognosis. 75 Newer techniques such as gene array technology that can evaluate a number of genes simultaneously have also shown additional potential sites of genetic abnormalities. 89 As more information on these techniques accumulates, patterns of gene abnormalities that correlate with prognosis may be found.
Molecular Immunology
Immunocompromised patients are more susceptible to many malignancies, and it is hypothesized that the immune system is involved in active surveillance for tumor cells. Patients with head and neck cancer in particular exhibit impairments in immune cell function and cytokine production. This suppression is present at the primary site, in the neck nodes, and systemically. 90 Tumor cells also secrete substances that further suppress the immune system. The treatments for head and neck cancers also cause immunosuppression.
As a part of the cellular immune system, major histocompatibility (MHC) class I proteins present peptide antigens to CD8 + cytotoxic T lymphocytes. Thus, loss of class I MHC activity may allow tumor cells to elude detection. IHC and LOH studies have shown abnormalities in MHC expression in many head and neck tumors. 91 
Molecular Detection of Head and Neck Cancers
Screening tests for head and neck cancers are being developed. These cancers are bathed in saliva, and cells exfoliate into this fluid. Analysis of saliva for abnormal cancer genes may allow tumor screening. An analysis of saliva from 44 head and neck cancers using a panel of PCR probes found microsatellite alterations present in both the saliva and the tumor in 36 cases. 92 Although saliva samples have the potential for screening for disease or recurrence, these tests are not currently in clinical use and have not yet been verified for clinical application.
Attempts have been made at finding p53 immunoglobulin G (IgG) antibodies in the serum and saliva of head and neck cancer patients with mixed results. In a study of 271 patients with oral squamous carcinoma, p53 antibodies were present in 25% of serum samples. 93 A low percentage of patients with head and neck cancer exhibit p53 antibody in their saliva. 94 These results are not surprising, given that p53 is abnormal in approximately 50% of head and neck cancers.
Abnormal promoter methylation is common in head and neck cancer genes. Using PCR, the presence of promoter hypermethylation can be detected in the serum and saliva of patients with head and neck cancer. 48, 49 Molecular Determination of Surgical Margins An analysis of the histologically negative margins from 25 head and neck cancer patients demonstrated p53 mutations in 13 of these patients. None of the patients with histologically and genetically negative margins recurred, while 5 of the 13 patients with p53 mutation in the margin recurred locally. 95 In another study, surgical margins from patients who underwent larynx cancer resections were tested for eIF4E status. 96 Of the 54 patients studied, 32 had eIF4E-positive margins. Of the 25 patients who recurred, 21 had eIF4E-positive margins. These studies show that histologically negative margins are not necessarily genetically negative and that genetically positive margins are more likely to recur. However, the relevance of this information in clinical management has not yet been fully elucidated.
Gene Therapy
The goal of gene therapy for cancer is to introduce genetic material into malignant cells to cause tumor regression. Once introduced, these genes may directly replace the function of a mutated gene, convert prodrugs into antineoplastic compounds, or induce other mechanisms that lead to cancer cell death.
Vectors are the means by which genes are delivered to the cell. Viral and nonviral vectors (eg, adenovirus, retrovirus, and liposomal) are used. Despite the high transfection efficiency of some vectors, delivery to all tumor cells is not technically feasible.
p53
Replacing a mutated p53 gene with a wild-type (normal) p53 gene is a potential approach to head and neck cancer treatment. This approach is limited by the lack of mutated p53 in many tumors and also by the current limitations of vector technology in delivering the gene. In a study of 17 patients with advanced recurrent or refractory unresectable head and neck cancer, treatment with delivery of the p53 gene using an adenoviral vector found only 2 patients with tumor regression of more than 50%. 97 An additional 17 patients with resectable disease were treated, and 2 remained disease-free for longer than 2 years.
ONYX-015
ONYX-015 is an adenovirus from which the E1B region has been deleted. E1B inactivates p53, thereby allowing virus replication. Consequently, ONYX-015 should be able to replicate only in cells lacking functional p53 and thus potentially target cancer cells. Some conflicting data have emerged regarding the specificity of ONYX-015, although its proponents claim that the most stringent tests, ie, those comparing cell lines differing only in p53 status, validate the efficacy of ONYX-015. 98 ONYX-015 was intratumorally injected in 22 patients with recurrent refractory head and neck cancer that had abnormal p53 immunochemistry. 99 A partial response was seen in 3 patients, and 2 had a minor response. A study involving 40 patients showed a partial response in 14%. 100 In another report, ONYX-015 was given in combination with cisplatin and 5-fluorouracil to treat 37 patients with recurrent head and neck cancer. 101 A partial response was seen in 15 patients. However, this was not a randomized trial, and it is not possible to conclude the true efficacy of ONYX-015 and chemotherapy combinations.
Alloantigen Therapy
Head and neck cancer commonly has reduced MHC expression. MHC antigens can incite a vigorous immune response. A potential application in treating head and neck cancer is the use of gene therapy to deliver a class I MHC. If the MHC is human but foreign to the patient, it can induce an antitumor response either by presenting tumor antigens or by itself being an antigen. Allovectin-7 is a gene therapy product that uses a liposomal vector and encodes the class I MHC HLA-B7.
A study of recurrent, advanced, unresectable head and neck cancer included 18 patients, all of whom were HLA-B7-negative. Patients received intratumoral injection of a gene transfer product (Allovectin-7), which resulted in complete or partial response in 4 patients. 102 A multi-institutional study, also of advanced unresectable head and neck cancer, included 60 patients who were HLA-B7-negative. After the first cycle of treatment, 23 patients had stable disease or a partial response and proceeded to the second cycle. After the second cycle and 16 weeks after the initiation of gene therapy, 6 patients had stable disease, 4 had a partial response, and 1 had a complete response. 103 
p16/p21/Rb
The tumor suppressor genes p16, p21, and Rb are frequently mutated in head and neck cancer and therefore are potential gene therapy targets. Studies in animal models support the potential for these genes in head and neck cancer therapy, 104, 105 but the application of vector technology is currently limited, as seen with p53 gene therapy.
Biologic Therapy

EGF/EGFR
The role of EGFR in head and neck cancer progression has led to the development of drugs to block this receptor. In a study of 16 patients with stage III and IV head and neck cancer, EGFR blocking antibody was combined with radiation therapy, and a complete response was seen in 13 patients. 106 This study was not randomized, so the true efficacy of the antibody cannot be assessed. EGFR blocking antibody in combination with cisplatin was also used in 12 patients with incurable recurrent or metastatic head and neck cancer. A complete response was achieved in 2 patients and a partial response in 4. 107 Again, due to the combination with cisplatin the true efficacy of the antibody cannot be assessed. Currently there are ongoing trials of EGFR blocking antibody.
Conclusions
Abnormalities of many genes critically involved in the regulation of the cell cycle are found in head and neck cancer. Detection of these genetic changes may assist in both the diagnosis and treatment of head and neck cancer in the future. Further research is needed to clarify how tumor genotype correlates with prognosis. In addition, simpler and less costly methods of detection need to be developed.
Although genetic and biologic therapies are still in the early phases of development, they hold promise for the treatment of head and neck cancer by addressing the fundamental defect of the malignant cell.
